A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin
| Autor: | René dePont Christensen, Bente Lund, Mansoor Raza Mirza, Anders Mellemgaard, Nina Keldsen, Jacob Christian Lindegaard, Kamma Bertelsen |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Oncology medicine.medical_specialty medicine.medical_treatment Phases of clinical research Deoxycytidine Disease-Free Survival Polyethylene Glycols Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Mucositis Humans Doxorubicin Survival rate Aged Ovarian Neoplasms Chemotherapy Dose-Response Relationship Drug business.industry Obstetrics and Gynecology Combination chemotherapy Middle Aged medicine.disease Gemcitabine Cystadenocarcinoma Serous Survival Rate Female business Febrile neutropenia medicine.drug |
| Zdroj: | Mirza, M R, Lund, B, Lindegaard, J C, Keldsen, N, Mellemgaard, A, Christensen, R D & Bertelsen, K 2010, ' A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin ', Gynecologic Oncology, vol. 119, no. 1, pp. 26-31 . https://doi.org/10.1016/j.ygyno.2010.06.022 |
| ISSN: | 0090-8258 |
| DOI: | 10.1016/j.ygyno.2010.06.022 |
| Popis: | Objective Treatment of epithelial ovarian cancer patients relapsing with a short treatment-free interval (TFI) after prior chemotherapy is unsatisfactory. This phase II trial evaluated the activity and feasibility of pegylated liposomal doxorubicin (PLD) plus gemcitabine in this setting. Methods Patients who had received prior platinum and paclitaxel with a TFI 0–12months received PLD 25mg/m 2 day 1 plus gemcitabine 800mg/m 2 day 1, 8 every 21days. Gemcitabine was dose escalated to 1000mg/m 2 day 1, 8 from course 2 in the absence of grade 3/4 toxicity. The primary endpoint was progression-free survival (PFS). Patients were stratified according to response to primary chemotherapy. Results Seventy-nine patients ( n =26 with CR on prior chemotherapy and TFI 6–12 months; n =20 with CR and TFI 0–6 months; n =33 with PR/SD and TFI 0–12 months) were enrolled. The median age was 59years (range 31–77years), and 33 patients had received ≥2 prior treatments. A median of five courses was delivered per patient (total 389 courses). Gemcitabine was dose escalated in 124 courses and reduced in 105 courses. No PLD dose reductions occurred. Grade 3/4 toxicities were febrile neutropenia ( n =4), PPE ( n =2), and mucositis ( n =2). One toxic death occurred (pneumonitis/alveolitis). Responses were complete in 5.1%, partial in 27.9%, and stable disease in 55.7%. Median OS and PFS were 12.5 and 6.4months, respectively. Conclusions The PLD–gemcitabine combination is an effective and well-tolerated salvage treatment for relapsed epithelial ovarian cancer and is a valid candidate for evaluation in a phase III trial. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect